CELU vs CLRB

Celularity Inc. vs Cellectar Biosciences, Inc. — Valuation Comparison 2026

CELU

Pharmaceutical Preparations
Celularity Inc.
Quality
4.9
out of 10
Value Trap
36
LOW
Price
$1.01
Last close
Models
7/13
Active
VS

CLRB

Pharmaceutical Preparations
Cellectar Biosciences, Inc.
Quality
3.7
out of 10
Value Trap
27
LOW
Price
$3.14
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CELU Fair ValueCELU Upside CLRB Fair ValueCLRB Upside
Bayesian DCF Intrinsic $1.38 -56.1%
Earnings Power Value Intrinsic $3.41 +256.8%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.27 +223.5% $0.17 -93.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $3.98 +293.9% $3.66 +16.4%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CELU vs CLRB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CELU vs CLRB — Which Stock Is More Undervalued?

CELU scores higher with a 4.9/10 quality rating vs CLRB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Celularity Inc. (CELU) and Cellectar Biosciences, Inc. (CLRB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CELU currently trades at $1.01 with a QOC of 4.9/10, while CLRB trades at $3.14 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).